ArticleScientific reports2025
Application of microfluidic technology and nanoencapsulation to amplify the antibacterial activity of clindamycin against a food born pathogen.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microfluidics in Intelligent Fresh Produce Preservation and Detection: From Precision Sensing to Active Delivery Systems.Comprehensive reviews in food science and food safety · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foodborne illnesses are often caused by microbial contamination during preparation or storage. In this work, stable nanoemulsions of clindamycin were prepared using Mentha piperita essential oil (MEO) as a nanocarrier delivery system. Response Surface Methodology was used to optimize the key variables for clindamycin nanoemulsion formulation, including 4.83, 2.83, and 0.14%w/w surfactant, essential oil, and clindamycin, respectively. The stability of MEO/clindamycin nanoemulsion (MEO/C NE) with a mean droplet size of 75.46 ± 3.2 nm was monitored over 3 months. The antibacterial activity of MEO/C NE and bulk compounds against E. coli bacterium was compared using a conventional method and a microfluidic chip. A significant difference in the antibacterial activity was observed by employing a microfluidic chip as compared to the conventional technique, probably due to a high contact surface area between the nanodroplets and bacterial membrane. In the microfluidic chip, the E. coli was completely inhibited in 30 min, whereas 3 h was needed for complete inhibition using the conventional method. The results of this study highlight the significance of nanoemulsion delivery systems to improve the antimicrobial activity of clindamycin and also microfluidic technology as a fast and reliable technique for examining antibiotics and nano delivery systems against microorganisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.